These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30136072)

  • 1. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer.
    Pastoriza JM; Karagiannis GS; Lin J; Lanjewar S; Entenberg D; Condeelis JS; Sparano JA; Xue X; Rohan TE; Oktay MH
    Clin Exp Metastasis; 2018 Oct; 35(7):613-623. PubMed ID: 30136072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Racial disparity in distant recurrence-free survival in patients with localized breast cancer: A pooled analysis of National Surgical Adjuvant Breast and Bowel Project trials.
    Kim G; Pastoriza JM; Qin J; Lin J; Karagiannis GS; Condeelis JS; Yothers G; Anderson S; Julian T; Entenberg D; Rohan TE; Xue X; Sparano JA; Oktay MH
    Cancer; 2022 Jul; 128(14):2728-2735. PubMed ID: 35578919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Race and recurrence in women who undergo neoadjuvant chemotherapy for breast cancer.
    Howard-McNatt M; Lawrence J; Melin SA; Levine EA; Shen P; Stewart JH
    Am J Surg; 2013 Apr; 205(4):397-401. PubMed ID: 23422317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer.
    Kyalwazi B; Yau C; Campbell MJ; Yoshimatsu TF; Chien AJ; Wallace AM; Forero-Torres A; Pusztai L; Ellis ED; Albain KS; Blaes AH; Haley BB; Boughey JC; Elias AD; Clark AS; Isaacs CJ; Nanda R; Han HS; Yung RL; Tripathy D; Edmiston KK; Viscusi RK; Northfelt DW; Khan QJ; Asare SM; Wilson A; Hirst GL; Lu R; Symmans WF; Yee D; DeMichele AM; van 't Veer LJ; Esserman LJ; Olopade OI
    JAMA Netw Open; 2023 Dec; 6(12):e2349646. PubMed ID: 38153734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial.
    Albain KS; Gray RJ; Makower DF; Faghih A; Hayes DF; Geyer CE; Dees EC; Goetz MP; Olson JA; Lively T; Badve SS; Saphner TJ; Wagner LI; Whelan TJ; Ellis MJ; Wood WC; Keane MM; Gomez HL; Reddy PS; Goggins TF; Mayer IA; Brufsky AM; Toppmeyer DL; Kaklamani VG; Berenberg JL; Abrams J; Sledge GW; Sparano JA
    J Natl Cancer Inst; 2021 Apr; 113(4):390-399. PubMed ID: 32986828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
    Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
    JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Racial Differences in the Use and Outcome of Neoadjuvant Chemotherapy for Breast Cancer: Results From the National Cancer Data Base.
    Killelea BK; Yang VQ; Wang SY; Hayse B; Mougalian S; Horowitz NR; Chagpar AB; Pusztai L; Lannin DR
    J Clin Oncol; 2015 Dec; 33(36):4267-76. PubMed ID: 26598753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial.
    Sparano JA; Wang M; Zhao F; Stearns V; Martino S; Ligibel JA; Perez EA; Saphner T; Wolff AC; Sledge GW; Wood WC; Davidson NE
    J Natl Cancer Inst; 2012 Mar; 104(5):406-14. PubMed ID: 22250182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features.
    Benefield HC; Reeder-Hayes KE; Nichols HB; Calhoun BC; Love MI; Kirk EL; Geradts J; Hoadley KA; Cole SR; Earp HS; Olshan AF; Carey LA; Perou CM; Troester MA
    JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 33442657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does race predict survival for women with invasive breast cancer?
    Walsh SM; Zabor EC; Stempel M; Morrow M; Gemignani ML
    Cancer; 2019 Sep; 125(18):3139-3146. PubMed ID: 31206623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
    Yothers G; Sargent DJ; Wolmark N; Goldberg RM; O'Connell MJ; Benedetti JK; Saltz LB; Dignam JJ; Blackstock AW;
    J Natl Cancer Inst; 2011 Oct; 103(20):1498-506. PubMed ID: 21997132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Borderline Estrogen Receptor-Positive Breast Cancers in Black and White Women.
    Benefield HC; Allott EH; Reeder-Hayes KE; Perou CM; Carey LA; Geradts J; Sun X; Calhoun BC; Troester MA
    J Natl Cancer Inst; 2020 Jul; 112(7):728-736. PubMed ID: 31742342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation.
    Keilty D; Nezafat Namini S; Swain M; Maganti M; Cil TD; McCready DR; Cescon DW; Amir E; Fleming R; Mulligan AM; Fyles A; Croke JM; Liu FF; Levin W; Koch CA; Han K
    Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):676-685. PubMed ID: 32407932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database.
    Bagegni NA; Tao Y; Ademuyiwa FO
    PLoS One; 2019; 14(9):e0222358. PubMed ID: 31536530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States.
    Iqbal J; Ginsburg O; Rochon PA; Sun P; Narod SA
    JAMA; 2015 Jan; 313(2):165-73. PubMed ID: 25585328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
    Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
    Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of estrogen receptor is associated with worse oncologic outcome in patients who were received neoadjuvant chemotherapy for breast cancer.
    Park YR; Lee J; Jung JH; Kim WW; Park CS; Lee RK; Chae YS; Lee SJ; Park JY; Park JY; Park HY
    Asian J Surg; 2020 Mar; 43(3):467-475. PubMed ID: 31204155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposing a novel molecular subtyping scheme for predicting distant recurrence-free survival in breast cancer post-neoadjuvant chemotherapy with close correlation to metabolism and senescence.
    Huang J; Zhang JL; Ang L; Li MC; Zhao M; Wang Y; Wu Q
    Front Endocrinol (Lausanne); 2023; 14():1265520. PubMed ID: 37900131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Black race independently predicts worse survival in uterine carcinosarcoma.
    Erickson BK; Doo DW; Zhang B; Huh WK; Leath CA
    Gynecol Oncol; 2014 May; 133(2):238-41. PubMed ID: 24613675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are There Differences in Treatment and Survival Between Poor, Older Black and White Women with Breast Cancer?
    Aggarwal H; Callahan CM; Miller KD; Tu W; Loehrer PJ
    J Am Geriatr Soc; 2015 Oct; 63(10):2008-13. PubMed ID: 26456765
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.